北京大学肿瘤医院

大众版专业版手机APP

返回

顶部

网站导航
当前位置:首页 >> 院所动态 >> 院所公告 > 正文

院所动态

通知公告

CSCO 2016 第三届北京黑色素瘤国际研讨会

发表时间:2016-10-11

    Welcoming

    On behalf of Peking University cancer hospital and CSCO (Chinese Society of Clinical Oncology), we are pleased to invite you to the 2016 CSCO 3rd Beijing international Melanoma Congress, to be held in Beijing on Oct 22-23, 2016.

    This conference will provide a highly interactive forum in which leading experts and clinical researchers in the field of melanoma can discuss recent advances in clinical trial data and scientific research. This blend of clinical and scientific research with clinical practice will offer the unique opportunity for participants to be updated on all aspects of melanoma research. Lectures and Panel discussions will highlight important developments in the field, including emerging therapies and implementation of new treatment strategies. We are certain you will gain valuable insight into the current status of preclinical melanoma research and the application of new trial data into clinical practice to ultimately improve patient care.

    We look forward to welcoming you to the 2016 CSCO 3rd Beijing international Melanoma Congress. We hope that you will also enjoy the beauty and culture of Beijing.

    Sincerely,

    QQ图片20161011131209.jpg       QQ图片20161011131220.jpg

      Jun Guo, MD, PhD  Chair        Keith T.Flaherty, MD  Chair


    Friday, Oct21,    2016
    1:00pm–8:00pmRegistration; Lobby in New Yunnan Hotel Beijing
    Saturday,OCT 22, 2016
    7:00am-8:30amRegistration & Breakfast
    8:30am-9:00amWelcome and Introductions
    Prof. Zhan Qimin (President of Peking University Health  Science Center,CHN)
    Prof. Sun Yan (Cancer Hospital Chinese Academy of Medical Sciences, CHN)
    Prof. Qin Shukui (Vice Chairman of Chinese Society of Clinical Oncology, CHN)
    Keynote Lecture
             Host: Prof. Qin Shukui (Bayi Hospital of PLA, Nanjing,CHN)
            Prof. Liang Jun (Peking University International Hospital,CHN)
    9:00am–9:30amThe Melanoma Treatment Landscape and Lessons from the Lab
    Georgina Long, MD (University of Sydney, Melanoma Institute of Australia,AUS)
    9:30am–10:00amOptimizing the immunotherapy /targeted therapy combinations
    Keith T. Flaherty, MD (Massachusetts General Hospital Cancer Center,USA)
    10:00am–10:10amCoffee & Tea
    Session 1: Neoadjuvant and adjuvant therapy of melanoma
       Host: Prof. Liu Weifeng (Beijing Jishuitan hospital, CHN)
          Prof. Li Hang(Peking University First Hospital,CHN)
    10:10am-10:30amPerspectives on earlier use of drugs with demonstrated activity at late stage
    Alexander Eggermont,MD,PhD(Institut de cander ologie GustaveRoussy, FR)
    10:30am–10:50amThe landscape of adjuvant therapy: where are we now
    Sanjiv Agarwala (Temple University School of Medicine, USA)
    10:50am–11:10amUpdate of results on adjuvant trials
    Helen Gogas, MD (University of Athens, GRE)
    11:10am–11:40amQuestion & Panel Discussion
    All attendees
    Satellite Meeting
    12:00-13:00
    1-MSD Company
    2-BMS Company
    Session 2: Immunotherapy
        Host: Prof. Lin Tongyu (Sun Yat-Sen University  Cancer Hospital, CHN)
            Prof. Tao Min (The 1st affiliated hospital of Soochow university, CHN)
    1:30pm-1:50pmLessons from the KEYNOTE 001 pembrolizumab trial
         Richard Kefford PhD, (University of Sydney, Melanoma Institute of Australia, AUS)
    1:50pm-2:10pmImmunotherapy for melanoma: current clinical advances
       Omid Hamid, MD(Angeles Clinic and Research Institute, Los Angeles, USA)
    2:10pm-2:45pmInterpreting the results of melanoma immunotherapy trials
       Merrick Ross, MD, (MD Anderson Cancer Center, USA)
    2:45pm-3:05pmBiomarkers of response to immunotherapy: are we close    to clinical implementation?
         Caroline Robert, MD ( Institut de canderologieGustaveRoussy, FRA)
    3:05pm–3:25pmSequential versus combination of immunotherapy and targeted therapy
       Steven O’Day, MD (John Wayne Cancer Institute, USA)
    3:25pm-3:35pmCoffee & Tea
    Session 3: Targeted Therapy
        Host: Prof. Lu Aiping(Peking University cancer hospital, CHN)
            Prof. Wu Di (The First hospital of Jilin University, CHN)
    3:35pm–3:55pmSignal transduction pathways in melanoma
         Jeffery Sosman, MD (Vanderbilt-Ingram Cancer Center, USA)
    3:55pm–4:15pmPotential targets in acral and mucosal melanoma
         Jun Guo, MD, PhD ( Peking University Cancer Hospital, CHN)
    4:15pm–4:35pmLong term responses with vemurafenib and dabrafenib
         Axel Hauschild, MD (University Hospital Schleswig-Holstein, GER)
    4:35pm–4:55pmMelanoma resistance: defining the final common pathway
         Dirk Schadendorf, MD (University Hospital Essen, GER)
    4:55pm–5:15pmNew therapeutic candidate targets
       Grant McArthur (Peter MacCallum Cancer Center,AUS)
    5:15pm–5:35pmQuestion &Panel Discussion
       All attendees
    SUNday, OCT 23, 2016
    Session 4: Local Therapy
        Host: Prof. Liu Jiwei (Dalian Medical University Hospital,CHN)
            Prof. Zhang Xiaoshi ( Sun Yat-Sen University Cancer Hospital,CHN)
    8:00am–8:20amOverview of oncolytic immunotherapy today
       Sanjiv Agarwala (Temple University School of Medicine, USA)
    8:20am–8:40amOncolytic immunotherapies changing the path of tumor resistance
       Robert Andtbacka,MD (University of Utah, USA)
    8:40am–9:00amNovel topical therapy for melanoma in situ using an immune modulator
    XiaoweiXu, PhD (Hospital of University of Pennsylvania, USA)
    Session 5: Acral & Mucosal    Melanoma Forum
        Host: Prof. Chen Xiaohong(Beijing Tongren Hospital)
            Prof. Fan Yun(Cancer Hospital of Zhejiang Province)
    9:00am-9:15amWhole genome sequencing of acral melanoma
    Graham Mann,Ph.D(University of Sydney, AUS)
    9:15am–9:30amWhole genome sequencing of mucosal melanoma
    Yan Kong, PhD(Peking University Cancer Hospital, CHN)
    9:30am-09:45amImmunotherapy in mucosal melanoma
    Georgina Long, MD (University of Sydney, Melanoma Institute of Australia, AUS)
    9:45am-10:00amClinical management of acral and mucosal melanoma
    Jun Guo (Peking University Cancer Hospital, CHN)
    10:00am–10:15amClinical management of uveal and conjunctive melanoma
    Richard Carvajal, MD (Columbia University Medical Center, USA)
    10:15am–10:30ampathology in melanoma, including the tumor microenvironment on anti-PD1
    Richard Scolyer, MD ( University of Sydney, Melanoma Institute of Australia, AUS )
    10:30am–10:40amCoffee & Tea
    10:40am–10:50amExperience and melanoma treatment in Taiwan
    Zhang Wenzhen, MD (Chang Gung Memorial Hospital, Taiwan,CHN)
    10:50am–11:00amExperience and melanoma treatment in Korea
    Sujin Lee, MD (Samsung Medical Center,Sungkyunkwan University, KOR)
    11:00am–11:10amCase Discussion 1: acral melanoma
    Lu Si, MD (Peking University Cancer Hospital &Institute, CHN)
    11:10am–11:20amCase Discussion 2: mucosal melanoma
    Anthony Ying, MD (Dr.Anthony C.H.Ying’ Clinic, Hong Kong, CHN) 
    Session 6: Oral Presentation
        Host:  Prof. Song Xin (Cancer Hospital of Yunnan Province,CHN)
            Prof. Chi Zhihong (Peking University Cancer Hospital& Institute, CHN)
    11:20am–11:26am Five high quality trials are helping define the role of radiotherapy in melanoma
    Elizabeth Paton, MD( University of Technology, Sydney, NSW, Australia)
    11:26am–11:32amA prognostic model based on preoperative inflammatory    markers for acral melanoma patients
    Rao Wang, MD (Sun Yat-Sen University Cancer Hospital,CHN)
    11:32am–11:38amThe natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from China
    Bin Lian, M.D ( Peking University Cancer Hospital &Institute,CHN)
    11:38am–11:44amGenotype and standard clinical features in 2793 melanomas
    Lili Mao, M.D ( Peking University Cancer Hospital &Institute,CHN)
    11:44am–11:50amPD-L1 Expression in Acral& Mucosal Melanoma and Its Clinical Significance
    Xue Bai, M.D ( Peking University Cancer Hospital &Institute,CHN)
    11:50am–12:00amClinical Activity of Pembrolizumab in Chinese patients with melanoma
    Xizhi Wen, M.D (Sun Yat-Sen University Cancer Hospital,CHN)
    12:00am–12:06amOrienX010 Oncolytic Viral Therapy in Phase Ⅰb Trial of    Intralesional Injection in Unresected Stage IIIC to IV Acral Melanoma Patients in China
    Chuanliang Cui,M.D ( Peking University Cancer Hospital &Institute,CHN)
    12:06am–12:30amPanel Discussion & Closing Remarks
    Jun Guo, MD, PhD (Peking University Cancer Hospital,CHN)

    报名参会具体事项:

    1、会议日期:2016年10月22日~23日,10月23日晚间撤离

    2、报到日期:10月21日(全天)

    3、报到地点:北京新云南皇冠假日酒店

    北京市朝阳区东北三环西坝河(太阳宫桥东北角云南大厦)

    4、会议费用:免注册费,提供会议用餐。

    5、参会方式:如有参会意向,请发送电子邮件至: BIMC_pku@126.com,标明参会人员姓名、单位、联系电话和email。联系电话:010-88196951

    6、注册参会人员将赠与幻灯文集,授予国家继续教育Ⅰ类学分4分。


    Gold:

    QQ图片20161011131253.jpgQQ图片20161011131301.jpg

    Silver:

    20161011131309.jpg

    Bronze:

    QQ图片20161011131354.jpgQQ图片20161011131400.jpg

    会议主办方:

    中国临床肿瘤学会

    北京市希思科临床肿瘤学研究基金会

    北京医学奖励基金会